Condensed Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:
Net (loss) income	$ (333,113)	$ 443,277
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation expense	12,124	13,114
Amortization of patents	58,778	58,360
Common stock and options issued for compensation, consulting and vendor services	324,279	512,846
Bad debt reversal		(295,488)
(Gain) loss on Joint Venture	567,550	259,291
Loss on Education Venture	10,455
Changes in operating assets and liabilities:
(Increase) in accounts receivable	(91,489)	(309,424)
(Increase) in inventories	(919,814)	(235,998)
Decrease to advances on contracts	996,949	273,885
(Increase) decrease to prepaid expenses and other current assets	(114,807)	137,117
(Increase) in other assets		(5,600)
(Decrease) in accounts payable	(629,479)	(530,190)
Increase in customer advances	49,441
Increase in accrued expenses	95,194	120,889
Net cash (used in) provided by operating activities	(3,360)	442,079
Cash flows from investing activities:
Investment in Medical Joint Venture	(263,009)	(259,291)
Investment in Joint Venture		(50,000)
Investment in Treasury Bills	(9,499,865)
Purchases of property and equipment	(66,130)	(3,111)
Payments for patent rights		(17,690)
Net cash used in investing activities	(9,964,805)	(330,092)
Cash flows from financing activities:
Proceeds from exercise of stock options	202,781	29,600
Proceeds from the sale of common stock		50,000
Net proceeds on Private Placement Offering	9,449,683
Proceeds from related party loan		50,000
Repayment from related party loan	(50,000)	(5,000)
Net cash provided by financing activities	9,602,464	124,600
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(365,701)	236,587
Cash and cash equivalents at beginning of period	1,147,198	165,249
Cash and cash equivalents at end of period	781,497	401,836
Supplemental disclosure of non cash investing and financing activities:
Shares issued to directors for the exercise of stock options	41,250	29,600
Shares issued to directors for compensation	55,200	45,000
Shares issued for conversion of notes payable and accrued interest		860,081
Shares issued to employees for exercise of stock options	104,615
Shares issued to employees in lieu of cash compensation	35,624	35,625
Shares issued to consultants for services	199,500	317,500
Shares issued to consultants for exercise of stock options	56,916
China Joint Venture
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
(Gain) loss on Joint Venture	(29,428)
Cash flows from investing activities:
Investment in Joint Venture	$ (135,801)